Capricor has bolstered the profile of its Duchenne muscular dystrophy candidate deramiocel (CAP-1002) with a new presentation of data showing how it limits heart damage in patients in the long term.
Cardiac Data Strengthens Capricor’s Duchenne Candidate As FDA Filing Gets Underway
Approval based on the Phase II results could come in early 2025, with a Phase III study already underway
